ENV-294 / Enveda Biosci - LARVOL DELTA

Enveda…announced that it has initiated two parallel Phase 2a clinical trials evaluating ENV-294, a first-in-class oral small molecule, for the treatment of moderate-to-severe Atopic Dermatitis (AD) and Asthma (Businesswire) - "The Phase 2a program is designed to evaluate the safety, tolerability, and efficacy of ENV-294 in two distinct patient populations, supporting the Company’s strategy to develop ENV-294 as a 'pipeline-in-a-product' for inflammatory diseases....Enveda plans to initiate a Phase 2b study in 2026."

New P2 trial • Asthma • Atopic Dermatitis • Immunology

Phase 1b Interim Analysis (Businesswire) - "In the interim analysis, ENV-294 demonstrated a rapid onset of action, with robust EASI improvements consistent with an anticipated JAK-inhibitor-like efficacy profile in patients with moderate-to-severe AD. Importantly, ENV-294 also maintained the expected biologic-like favorable safety profile consistent with earlier Phase 1a healthy volunteer studies and 3-month GLP toxicology studies."

P1 data • Atopic Dermatitis

Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis (Businesswire) - "Enveda...announced the successful completion of its Phase 1 clinical trial of ENV-294, a novel oral therapeutic for atopic dermatitis, asthma, and beyond...ENV-294 was found to be well-tolerated with a favorable safety profile across all dose levels, with no dose-limiting toxicities or serious adverse events reported. Pharmacokinetic data demonstrated dose-proportional exposure and support the potential for once-daily oral dosing. The Phase 1b trial is designed to evaluate the safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy of ENV-294 in patients with moderate to severe atopic dermatitis. Phase 1b initiation is currently expected to begin in the second half of 2025."

P1 data • Trial status • Asthma • Atopic Dermatitis

Enveda Biosciences Named One of Biotech’s Most Promising Startups by Endpoints News (Businesswire) - "Enveda’s platform and library has already yielded four development candidates, with three additional candidates in fast follow. The two lead compounds both target inflammation. The first addresses inflammatory bowel disease through a novel MOA and biodistribution. The second, addressing atopic dermatitis, inhibits neutrophil migration through a unique MOA, blocking multiple chemoattractant pathways with a single molecule. Both of these compounds are slated to enter clinical trials in 2024."

New trial • Atopic Dermatitis • Immunology • Inflammatory Bowel Disease